Transaction in Own Shares

    Transaction in Own Shares
             
Novo Nordisk A/S - Share repurchase programme


On 15 August 2008 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an
amount of up to DKK 1.7 billion in the period from 15 August 2008 to
19 December 2008.

Since the announcement as of 3 November 2008, the following
transactions have been made under the programme:


                  Number of    Average     Transaction
                   shares   purchase price value, DKK
Accumulated, last
announcement      3,088,500                866,659,744
3 November 2008    58,000      307.0700    17,810,060
4 November 2008    50,000      321.4400    16,072,000
5 November 2008    80,000      316.0400    25,283,200
6 November 2008    50,000      310.3600    15,518,000
7 November 2008    50,000      305.6100    15,280,500
Accumulated under
the programme     3,376,500                956,623,504


Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 93,950 B-shares in the
period from 3 November 2008 to 7 November 2008. The shares in these
transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of
24,426,590 treasury shares, corresponding to 3.9% of the share
capital. The total amount of shares in the company is 634,000,000
including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,550
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.

Further information:

Media:                 Investors:

Elin K Hansen          Mads Veggerby Lausten
Tel: [phone]   Tel: [phone]
[e-mail]    [e-mail]

                       Hans Rommer
                       Tel: [phone]
                       [e-mail]
In North America:
Sean Clements
Tel: [phone]
[e-mail]


Company Announcement no 74 / 2008

http://hugin.info/2013/R/1268179/280025.pdf


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.